NCT04688034View on ClinicalTrials.gov

Safety and Tolerability Study of OP-724 in Liver Cirrhosis Patients by HIV/HCV with Hemophilia.

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

March 15, 2021

Primary Completion Date

July 5, 2022

Study Completion Date

July 5, 2022

Conditions
Liver Cirrhosis
Interventions
DRUG

OP-724

Twice a week for 4 hours continuous intravenous administration of OP-724.

Trial Locations (1)

113-8677

Tokyo Metropolitan Komagome Hospital, Bunkyo-Ku

Sponsors
All Listed Sponsors
collaborator

Japan Agency for Medical Research and Development

OTHER_GOV

collaborator

Ohara Pharmaceutical Co., Ltd.

INDUSTRY

lead

Kiminori Kimura, MD

OTHER